The SGLT2 inhibitor empagliflozin has been approved in Europe for the treatment of adults with HFrEF. This approval is based on results from the EMPEROR-Reduced trial , in which the risk of CV death or hospitalization due to heart failure was reduced by 25% in the empagliflozin group compared to the placebo group. These findings were consistent in HFrEF patients with and without T2DM. Key secondary endpoint of risk of first and recurrent hospitalization for heart failure was reduced by 30% in the empagliflozin group compared to the placebo group and empagliflozin slowed kidney function decline.

The EMPEROR-Reduced trial is part of the EMPOWER clinical program, in which the effect of empagliflozin is investigated in patients across the spectrum of cardio-renal-metabolic conditions.

Source: press release Boehringer Ingelheim June 21, 2021